{"title_page": "Centanafadine", "text_new": "{{Drugbox\n| IUPAC_name = (1''R'',5''S'')-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane\n| image = Centanafadine.svg\n| width = 180\n\n<!--Clinical data-->\n| tradename =\n| routes_of_administration =\n| legal_US = Investigational New Drug\n| legal_status = \n\n<!--Identifiers-->\n| CAS_number = 924012-43-1\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = D2A6T4UH9C\n| ATC_suffix =\n|  PubChem = 16095349\n|  ChemSpiderID = 17253639\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10697\n\n<!--Chemical data-->\n| C=15 | H=15 | N=1\n| molecular_weight = 209.28 g/mol\n| smiles = C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4\n| StdInChI = 1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1\n| StdInChIKey = HKHCSWPSUSWGLI-CABCVRRESA-N\n}}\n\n{| class=\"wikitable floatright\" style=\"font-size:small;\"\n|+ Centanafadine <ref name=nM>{{cite news|title=Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial|url=http://www.neurovance.com/wp-content/uploads/2014/05/Press_Release_Neurovance_EB-1020_Data_050714.pdf|access-date=14 January 2018|publisher=Neurovance}}</ref>\n|-\n! Site !! IC<sub>50</sub> (nM) !! Action !! Ref\n|-\n| {{abbrlink|SERT|Serotonin transporter}} || 83 nM || Blocker || <ref name=\"nM\" />\n|-\n| {{abbrlink|NET|Norepinephrine transporter}} || 6 nM || Blocker || <ref name=\"nM\" />\n|-\n| {{abbrlink|DAT|Dopamine transporter}} || 38 nM || Blocker || <ref name=\"nM\" />\n|}\n\n'''Centanafadine''' ([[International Nonproprietary Name|INN]]) (former developmental code name '''EB-1020''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) that began its [[drug development|development]] with [[Euthymics Bioscience]] after they acquired [[DOV Pharmaceutical]]. It was developed as a treatment for [[attention-deficit hyperactivity disorder]] (ADHD) and inhibits the [[reuptake]] of [[norepinephrine]], [[dopamine]], and [[serotonin]] with a ratio of 1:6:14, respectively.<ref name=\"nM\" /><ref>{{cite web | url=http://www.neurovance.com/science/ | title=3-Neurotransmitters, 1-Molecule: Optimized Ratios | publisher=Neurovance| date= }}</ref><ref>{{cite web | url=http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | title=EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD | publisher=Neurovance}}</ref><ref>{{cite journal | vauthors = Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI | title = Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder | journal = Synapse | volume = 66 | issue = 6 | pages = 522\u201332 | date = June 2012 | pmid = 22298359 | doi = 10.1002/syn.21538 }}</ref> In 2011, [[Euthymics Bioscience]] spun off its development of centanafadine to a new company called Neurovance.<ref name=euthymics>{{cite web|title=Euthymics|url=http://euthymics.com/|website=Ethismos Research Inc.|access-date=14 January 2018|ref=euthymics}}</ref><ref>{{cite news|title=EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD|url=http://www.neurovance.com/wp-content/uploads/2014/04/Neurovance_120711.pdf|access-date=14 January 2018|publisher=Neurovance|date=December 7, 2011}}</ref> In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.<ref>{{cite web|title=Otsuka Pharmaceutical to Acquire Neurovance, Inc.|url=https://www.otsuka-us.com/discover/articles-1000|publisher=Otsuka|access-date=14 January 2018|date=}}</ref> As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.<ref name=\"Otsuka\">{{cite web|title=Otsuka U.S. Research & Development Programs|url=https://www.otsuka-us.com/media/images/AR-5-11-2017-OTS-US-Pipeline-Graphic-v02_959.jpg|website=Otsuka U.S.|publisher=Otsuka|access-date=14 January 2018}}{{Dead link|date=November 2019 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>\n== See also ==\n* [[Amitifadine]]\n* [[Bicifadine]]\n* [[Dasotraline]]\n* [[DOV-216,303]]\n* [[Tesofensine]]\n\n== References ==\n{{Reflist|2}}\n\n== External links ==\n* [http://adisinsight.springer.com/drugs/800035830 Centanafadine - AdisInsight]\n\n{{Monoamine reuptake inhibitors}}\n\n[[Category:Naphthalenes]]\n[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]\n[[Category:Stimulants]]\n[[Category:Nitrogen heterocycles]]\n[[Category:Cyclopropanes]]\n\n{{nervous-system-drug-stub}}\n", "text_old": "{{Drugbox\n| IUPAC_name = (1''R'',5''S'')-1-naphthalen-2-yl-3-azabicyclo[3.1.0]hexane\n| image = Centanafadine.svg\n| width = 180\n\n<!--Clinical data-->\n| tradename =\n| routes_of_administration =\n| legal_US = Investigational New Drug\n| legal_status = \n\n<!--Identifiers-->\n| CAS_number = 924012-43-1\n| ATC_suffix =\n|  PubChem = 16095349\n|  ChemSpiderID = 17253639\n| KEGG_Ref = {{keggcite|correct|kegg}}\n| KEGG = D10697\n\n<!--Chemical data-->\n| C=15 | H=15 | N=1\n| molecular_weight = 209.28 g/mol\n| smiles = C1=C(C=CC2=CC=CC=C12)[C@@]34C[C@@H]3CNC4\n| StdInChI = 1S/C15H15N/c1-2-4-12-7-13(6-5-11(12)3-1)15-8-14(15)9-16-10-15/h1-7,14,16H,8-10H2/t14-,15+/m1/s1\n| StdInChIKey = HKHCSWPSUSWGLI-CABCVRRESA-N\n}}\n\n{| class=\"wikitable floatright\" style=\"font-size:small;\"\n|+ Centanafadine <ref name=nM>{{cite news|title=Neurovance's EB-1020 SR for Adult ADHD Shows Stimulant-Like Efficacy and Good Tolerability in Phase 2a Trial|url=http://www.neurovance.com/wp-content/uploads/2014/05/Press_Release_Neurovance_EB-1020_Data_050714.pdf|access-date=14 January 2018|publisher=Neurovance}}</ref>\n|-\n! Site !! IC<sub>50</sub> (nM) !! Action !! Ref\n|-\n| {{abbrlink|SERT|Serotonin transporter}} || 83 nM || Blocker || <ref name=\"nM\" />\n|-\n| {{abbrlink|NET|Norepinephrine transporter}} || 6 nM || Blocker || <ref name=\"nM\" />\n|-\n| {{abbrlink|DAT|Dopamine transporter}} || 38 nM || Blocker || <ref name=\"nM\" />\n|}\n\n'''Centanafadine''' ([[International Nonproprietary Name|INN]]) (former developmental code name '''EB-1020''') is a [[serotonin-norepinephrine-dopamine reuptake inhibitor]] (SNDRI) that began its [[drug development|development]] with [[Euthymics Bioscience]] after they acquired [[DOV Pharmaceutical]]. It was developed as a treatment for [[attention-deficit hyperactivity disorder]] (ADHD) and inhibits the [[reuptake]] of [[norepinephrine]], [[dopamine]], and [[serotonin]] with a ratio of 1:6:14, respectively.<ref name=\"nM\" /><ref>{{cite web | url=http://www.neurovance.com/science/ | title=3-Neurotransmitters, 1-Molecule: Optimized Ratios | publisher=Neurovance| date= }}</ref><ref>{{cite web | url=http://euthymics.com/wp-content/uploads/2012/10/White-Paper-EB1020-092612.pdf | title=EB-1020, a Non-Stimulant Norepinephrine and Dopamine - Preferring Reuptake Inhibitor for the Treatment of Adult ADHD | publisher=Neurovance}}</ref><ref>{{cite journal | vauthors = Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI | title = Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder | journal = Synapse | volume = 66 | issue = 6 | pages = 522\u201332 | date = June 2012 | pmid = 22298359 | doi = 10.1002/syn.21538 }}</ref> In 2011, [[Euthymics Bioscience]] spun off its development of centanafadine to a new company called Neurovance.<ref name=euthymics>{{cite web|title=Euthymics|url=http://euthymics.com/|website=Ethismos Research Inc.|access-date=14 January 2018|ref=euthymics}}</ref><ref>{{cite news|title=EUTHYMICS BIOSCIENCE, INC. PRESENTS DATA THAT SUPPORT ADVANCING EB-1020 INTO CLINICAL TRIALS FOR ADULT ADHD|url=http://www.neurovance.com/wp-content/uploads/2014/04/Neurovance_120711.pdf|access-date=14 January 2018|publisher=Neurovance|date=December 7, 2011}}</ref> In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.<ref>{{cite web|title=Otsuka Pharmaceutical to Acquire Neurovance, Inc.|url=https://www.otsuka-us.com/discover/articles-1000|publisher=Otsuka|access-date=14 January 2018|date=}}</ref> As of January 2018, Otsuka's pipeline indicates it is in Phase III clinical trials.<ref name=\"Otsuka\">{{cite web|title=Otsuka U.S. Research & Development Programs|url=https://www.otsuka-us.com/media/images/AR-5-11-2017-OTS-US-Pipeline-Graphic-v02_959.jpg|website=Otsuka U.S.|publisher=Otsuka|access-date=14 January 2018}}{{Dead link|date=November 2019 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>\n== See also ==\n* [[Amitifadine]]\n* [[Bicifadine]]\n* [[Dasotraline]]\n* [[DOV-216,303]]\n* [[Tesofensine]]\n\n== References ==\n{{Reflist|2}}\n\n== External links ==\n* [http://adisinsight.springer.com/drugs/800035830 Centanafadine - AdisInsight]\n\n{{Monoamine reuptake inhibitors}}\n\n[[Category:Naphthalenes]]\n[[Category:Serotonin-norepinephrine-dopamine reuptake inhibitors]]\n[[Category:Stimulants]]\n[[Category:Nitrogen heterocycles]]\n[[Category:Cyclopropanes]]\n\n{{nervous-system-drug-stub}}\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Centanafadine"}
